

CEAPRO TACKLES DIABETES HEAD ON

CeaProve® identifies the risk for type 2 diabetes at its earliest stage

Edmonton, Alberta – March 7, 2007 – Ceapro Inc. (CZO – TSXV) has developed an innovative technology to deal directly with diabetes. As a spin-off from the University of Toronto in 1995, the Company has taken more than 12 years to develop a scientifically-sound diagnostic test that identifies people at risk, long before they develop type-2 diabetes and suffer from its complications.

CeaProve® enables people with impaired glucose tolerance or pre-diabetes, one of the first stages of diabetes development, to detect their condition. This condition can precede diabetes by as much as five to ten years. The good news is research has shown that pre-diabetes can be reversed with simple lifestyle changes such as walking 30 minutes a day, losing 10 lbs, and decreasing dietary fat intake, especially saturated fat. The issue is that many people are not aware that they are affected until they already have diabetes with advanced complications.

Now with a simple test that consists of eating 6 oat-wafers and undergoing a finger prick, people can know years ahead of time if they are heading down the path to diabetes. The test - when repeated at six month intervals - can also show if lifestyle changes are being effective or if more treatment is needed.

Ceapro has tested CeaProve® in the workplace of several prominent businesses in Edmonton that are interested in helping their employees monitor and preserve their health.

“In screening ‘normal’ populations, as many as 40% were found to be at risk for pre-diabetes and 10% were at risk for diabetes. These statistics parallel the recent findings of the Ontario population study published in *The Lancet* ⁽¹⁾ and reported in the *Globe & Mail*. By not identifying pre-diabetes, a large number of people at risk were missed in that study, indicating the problem is much, much larger than initially thought” stated Dr. Sarah Lord, Manager of Diabetes Technology for Ceapro Inc.

Over 90% of tested volunteers were unaware of their risk for diabetes; they took the results of the test as a wake-up call to start taking better care of themselves. Of the population studied, 60% were overweight, 56% were over the age of 40, 44 % had a family history of diabetes and over 57% had more than two risk factors for the disease.

The workplace is a good place to screen people for early indicators of diabetes and heart disease. Point of care technology like CeaProve® is ideal for workplace programs as education and follow-up testing can subsequently be conducted within the work environment.

Ceapro is talking to regional health authorities and governments about early testing with CeaProve®. This product could help these institutions better manage diabetes in their regions by identifying people at risk and prescribing treatment for them early, before complications arise. This could represent huge health care cost savings to all involved.

Ceapro expects to have CeaProve® available in commercial quantities within the next 45 days. The product will likely be released through regional health initiatives and may also be available through pharmacies and medical laboratories.

⁽¹⁾The Lancet Volume 369, Issue 9563, 3 March 2007-9 March 2007, Pages 750-756
<http://www.sciencedirect.com/science>

About Ceapro Inc.

Ceapro Inc is a Canadian growth stage biotechnology company. Ceapro's core technology is the extraction of functional, active ingredients from plants and other renewable resources. We add further value to our extracts by manufacturing medical and therapeutic products, and by supporting the use of our extracts in products for human and animal health. We have also introduced health and wellness services employing our CeaProve(R) diagnostic technology. Our most recent initiative is the creation of Ceapro BioEnergy Inc. (CBE), a wholly-owned subsidiary to utilize Ceapro's proprietary technology for the production of ethanol and value-added products. Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, visit our website at www.ceapro.com.

For more information contact:

Dr. Sarah Lord
Manager of Diabetes Technology
Ceapro Inc.
Telephone (Edmonton): (780) 421-4555

Nicole Blanchard, Investor Relations
Managing Partner
Sun International Communications
Telephone (Montreal): (450) 627-6600

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.